Navigation Links
Viral Genetics Information Now Available Through OTCIQ.com and Pink Sheets Website
Date:7/8/2009

>http://www.pinksheets.com/content/doc/ps/Disclosure/Guidelines/2.pdf. The guidelines are intended to substantially follow the reporting requirements of registrants under Section 12 of the Securities Exchange Act administered by the SEC, although the requirements are voluntary when an issuer is not actually registered with the SEC.

Viral Genetics is now completing an Initial Disclosure Filing which will include un-audited financial statements from the period October 1, 2007 until the most recent quarter-end, as well as general company information, plan of operations, information about share issuances and capital structure, and other updates. In the interim, the company will make ongoing Current Reports under the OTCIQ system.

About Viral Genetics, Inc.:

Viral Genetics, Inc. is a biotechnology company that discovers and develops immune-based therapies for HIV, AIDS and other autoimmune diseases using its thymus nuclear protein compound (TNP). The Company recently licensed technology developed by M. Karen Newell, PhD from the University of Colorado, that appears to explain TNP and provide a means to optimize therapies based on TNP for future clinical trials. Viral Genetics believes that its investigational HIV/AIDS drug based on TNP, called VGV-1, represents a unique approach to treating HIV due to the apparently novel mechanism, low toxicity profile, simple dosing regimen, and short-course of treatment. As a type of immune-based therapy, VGV-1 focuses on boosting the immune system to allow the body to fight HIV more efficiently. VGV-1 has been studied in five human clinical trials for the treatment of HIV/AIDS. Online at www.viralgenetics.com

SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS:'/>"/>

SOURCE Viral Genetics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
2. GlaxoSmithKline and Anacor Pharmaceuticals Form Alliance to Develop Systemic Antivirals and Antibiotics Based on Boron Chemistry
3. Companys Partner Completes Trial Production of a New Antiviral Medicine
4. Cell Genesys Announces Sale of Lentiviral Gene Delivery Technology for $12 Million
5. SAFC Pharma to Increase Viral Product Manufacturing Capacity
6. MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
7. Lentigen Licenses Fundamental Lentiviral Vector Technology Patent From the University of Cambridge
8. Peregrine Pharmaceuticals Reports Studies Published in Science Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
9. World Hepatitis Alliance Calls on Governments to Take Urgent Action to Tackle Chronic Viral Hepatitis B & C Epidemic
10. Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers
11. Researchers decode viral process that prepares cells for HIV infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Using a bio-mimicking analog of one of nature,s ... international research team led by Alejandro Briseno of ... major step in developing long-sought polymer architecture to ... use in electronic devices. , Briseno, with ... others at Stanford University and Dresden University of ...
(Date:9/30/2014)... 30, 2014 Shimadzu Scientific Instruments ... easy-to-use and highly precise tool for measuring displacement ... elongation. With 1000-mm maximum movement distance, the DSES-1000 ... a gauge length of 10 mm. In addition, ... above 50-mm stroke and within +/- 100 µm ...
(Date:9/30/2014)... Proove Biosciences , the commercial and research leader in ... test built upon research from their published P.A.I.N. Study. ... physicians with an objective way to understand theirs patient’s ... individuals. With this new test, physicians will be able ... that will affect their pain tolerance. , The P.A.I.N. ...
(Date:9/30/2014)... -- CORD:USE Cord Blood Bank – www.corduse.com ... into an Equity and Exclusive Services Agreement with Tianhe Stem ... patented technologies for the isolation of human cord blood-derived ... performing Phase I/II clinical trials in China ... Tianhe,s Stem Cell Educator Therapy showing that the therapy ...
Breaking Biology Technology:Blades of grass inspire advance in organic solar cells 2Blades of grass inspire advance in organic solar cells 3Shimadzu’s New Long-Travel Extensometer Increases Precision for Soft Material Testing 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 2CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 3CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 4
... BOSTON, Oct. 3 PAREXEL International,Corporation (Nasdaq: PRXL ... on Wednesday, October 24, 2007 after the close of ... website at, http://www.parexel.com and on the PR Newswire ... a conference call and live webcast at 10:00 a.m. ...
... for its best-practices approach ... and easy-to-use functionality, ... the leading,provider of award-winning Web-based employee performance and talent,management ... Resources,Product Award from Human Resource Executive(R) magazine. Halogen,eSuccession(TM) was ...
... Healthcare II Fund More Than Doubles Assets Under Management, ... a rapidly growing European venture capital firm, today announced,the ... venture fund, Gilde,Healthcare II (GHC II). The new fund, ... largest venture funds raised to invest in European,healthcare opportunities. ...
Cached Biology Technology:PAREXEL Announces Date of First Quarter Fiscal Year 2008 Earnings Release and Conference Call 2Halogen Software Wins Top Human Resource Product Award 2Halogen Software Wins Top Human Resource Product Award 3Gilde Healthcare Partners Closes EUR 150 Million European Healthcare Venture Fund 2
(Date:9/30/2014)... Journal of Medicine reports positive results of a ... the subset of lung cancer marked by rearrangement of ... patients with advanced non-small cell lung cancer testing positive ... percent, with 3 complete responses and 33 partial responses. ... the disease to resume its growth after being slowed ...
(Date:9/30/2014)... N.C. -- Pollution in urban and farm runoff in ... new study finds. , The study, published Tuesday ... that nitrogen in the runoff ends up in algae ... on the animals, eyes, flippers and internal organs. , ... the National Oceanic and Atmospheric Administration (NOAA) conducted the ...
(Date:9/30/2014)... you want your doctor to know what goes wrong with ... good idea to know what "normal" actually is. That,s where ... of the FASEB Journal comes in. ... transcriptomea key set of molecules that can help scientists "see" ... time. What,s more, they found never-before-detected gene activity and that ...
Breaking Biology News(10 mins):NEJM: Crizotinib effective in Phase 1 trial against ROS1 lung cancer 2Pollution linked to lethal sea turtle tumors 2Pollution linked to lethal sea turtle tumors 3Scientists identify which genes are active in muscles of men and women 2
... 2008--As atmospheric CO2 levels rise, methods to mitigate these ... the July-August 2008 issue of Soil Science Society ... soils as a C sink in different regions in ... Development (Canada), the National Institute of Agricultural Technology, the ...
... person is losing a significant amount of weight, they ... may overlook changes happening in their bones. During weight ... breaking down old bone and forming new bone - ... density is decreasing, causing increased fragility. In a new ...
... a new technology that promises to dramatically increase ... crops, such as Bermudagrass, switchgrass, Napiergrassand even yard ... biomass sources such as grasses is desirable because ... Joy Peterson, professor of microbiology and chair of ...
Cached Biology News:Soil's carbon storage capacity investigated 2Soil's carbon storage capacity investigated 3Accelerated bone turnover remains after weight loss 2New UGA biomass technology dramatically increases ethanol yield from grasses and yard waste 2New UGA biomass technology dramatically increases ethanol yield from grasses and yard waste 3
Request Info...
NATIVE RAT OSTEOCALCIN...
... to Opsin 1 ( Abpromise for all ... peptide: YEDSTHASIFTYT, corresponding to amino acids 14/26 of ... corresponding to amino acids 18/30 of tiger red ... immunogen. Entrez Gene ID: ...
EnzChek Ultra Xylanase Assay Kit *500 assays*...
Biology Products: